{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T08:38:00Z","timestamp":1790411880914,"version":"4.1.0"},"reference-count":169,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,6,13]],"date-time":"2021-06-13T00:00:00Z","timestamp":1623542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,13]],"date-time":"2021-06-13T00:00:00Z","timestamp":1623542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004442","name":"Narodowym Centrum Nauki","doi-asserted-by":"publisher","award":["2015\/19\/B\/NZ7\/02847"],"award-info":[{"award-number":["2015\/19\/B\/NZ7\/02847"]}],"id":[{"id":"10.13039\/501100004442","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the central nervous system (CNS) leading to mental deterioration and devastation, and eventually a fatal outcome. AD affects mostly the elderly. AD is frequently accompanied by hypercholesterolemia, hypertension, atherosclerosis, and diabetes mellitus, and these are significant risk factors of AD. Other conditions triggered by the progression of AD include psychosis, sleep disorders, epilepsy, and depression. One important comorbidity is Down\u2019s syndrome, which directly contributes to the severity and rapid progression of AD. The development of new therapeutic strategies for AD includes the repurposing of drugs currently used for the treatment of comorbidities. A better understanding of the influence of comorbidities on the pathogenesis of AD, and the medications used in its treatment, might allow better control of disease progression, and more effective pharmacotherapy.<\/jats:p><jats:p><jats:bold>Graphic abstract<\/jats:bold><\/jats:p>","DOI":"10.1007\/s43440-021-00293-5","type":"journal-article","created":{"date-parts":[[2021,6,13]],"date-time":"2021-06-13T17:02:27Z","timestamp":1623603747000},"page":"1565-1581","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["A review of the mechanisms underlying selected comorbidities in Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"73","author":[{"given":"Karolina","family":"Maciejewska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamila","family":"Czarnecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3438-7509","authenticated-orcid":false,"given":"Pawe\u0142","family":"Szyma\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,13]]},"reference":[{"key":"293_CR1","unstructured":"Patterson C. World Alzheimer Report 2018. The State of the Art of Dementia Research: New Frontiers. London, UK: Alzheimer\u2019s disease International; 2018. https:\/\/www.alz.co.uk\/research\/WorldAlzheimerReport2018.pdf."},{"key":"293_CR2","unstructured":"Prince M, Wimo A, Guerchet M, Ali GC, Wu YT, Prina M. World Alzheimer Report 2015. The Global Impact of Dementia: An Analysis of Prevalence, Incidence, Cost and Trends. London: Alzheimer\u2019s disease International; 2015. https:\/\/www.alz.co.uk\/research\/WorldAlzheimerReport2015.pdf."},{"key":"293_CR3","unstructured":"Prince M, Guerchet MM, Prina M. The Epidemiology and Impact of Dementia: Current State and Future Trends. WHO Thematic Briefing. 2015. https:\/\/www.who.int\/mental_health\/neurology\/dementia\/dementia_thematicbrief_epidemiology.pdf."},{"issue":"4","key":"293_CR4","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"},{"issue":"17","key":"293_CR5","doi-asserted-by":"publisher","first-page":"5610","DOI":"10.1016\/j.bmc.2015.07.029","volume":"23","author":"M Bajda","year":"2015","unstructured":"Bajda M, Jo\u0144czyk J, Malawska B, Czarnecka K, Girek M, Olszewska P, et al. Synthesis, biological evaluation and molecular modeling of new tetrahydroacridine derivatives as potential multifunctional agents for the treatment of Alzheimer\u2019s disease. Bioorg Med Chem. 2015;23(17):5610\u20138.","journal-title":"Bioorg Med Chem"},{"issue":"9","key":"293_CR6","doi-asserted-by":"publisher","first-page":"952","DOI":"10.2174\/1567205013666160314150501","volume":"13","author":"J Dorszewska","year":"2016","unstructured":"Dorszewska J, Prendecki M, Oczkowska A, Dezor M, Kozubski W. Molecular basis of familial and sporadic Alzheimer\u2019s disease. Curr Alzheimer Res. 2016;13(9):952\u201363.","journal-title":"Curr Alzheimer Res"},{"issue":"2","key":"293_CR7","doi-asserted-by":"publisher","first-page":"106","DOI":"10.5114\/fn.2019.84828","volume":"57","author":"M Prendecki","year":"2019","unstructured":"Prendecki M, Florczak-Wyspianska J, Kowalska M, Ilkowski J, Grzelak T, Bialas K, et al. APOE genetic variants and apoE, miR-107 and miR-650 levels in Alzheimer\u2019s disease. Folia Neuropathol. 2019;57(2):106\u201316.","journal-title":"Folia Neuropathol"},{"issue":"2","key":"293_CR8","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s11682-013-9272-x","volume":"8","author":"L Ungar","year":"2014","unstructured":"Ungar L, Altmann A, Greicius MD. Apolipoprotein E, gender, and Alzheimer\u2019s disease: an overlooked, but potent and promising interaction. Brain Imaging Behav. 2014;8(2):262\u201373.","journal-title":"Brain Imaging Behav"},{"issue":"4","key":"293_CR9","doi-asserted-by":"publisher","first-page":"264","DOI":"10.2174\/1568026619666190128125912","volume":"19","author":"M Saxena","year":"2019","unstructured":"Saxena M, Dubey R. Target enzyme in Alzheimer\u2019s disease: acetylcholinesterase inhibitors. Curr Top Med Chem. 2019;19(4):264\u201375.","journal-title":"Curr Top Med Chem"},{"issue":"8","key":"293_CR10","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1111\/jphp.12919","volume":"70","author":"S Verma","year":"2018","unstructured":"Verma S, Kumar A, Tripathi T, Kumar A. Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in Alzheimer\u2019s disease therapy. J Pharm Pharmacol. 2018;70(8):985\u201393.","journal-title":"J Pharm Pharmacol"},{"issue":"4","key":"293_CR11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.bioorg.2011.05.001","volume":"39","author":"P Szyma\u0144ski","year":"2011","unstructured":"Szyma\u0144ski P, Markowicz M, Mikiciuk-Olasik E. Synthesis and biological activity of derivatives of tetrahydroacridine as acetylcholinesterase inhibitors. Bioorg Chem. 2011;39(4):138\u201342.","journal-title":"Bioorg Chem"},{"key":"293_CR12","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ejphar.2015.02.022","volume":"754","author":"XL Wang","year":"2015","unstructured":"Wang XL, Xiong Y, Yang Y, Tuo QZ, Wang XC, Chen R, et al. A novel tacrine-dihydropyridine hybrid (-)SCR1693 induces tau dephosphorylation and inhibits Abeta generation in cells. Eur J Pharmacol. 2015;754:134\u20139.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"293_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/cbdd.12633","volume":"87","author":"RS Keri","year":"2016","unstructured":"Keri RS, Quintanova C, Chaves S, Silva DF, Cardoso SM, Santos MA. New tacrine hybrids with natural-based cysteine derivatives as multitargeted drugs for potential treatment of Alzheimer\u2019s disease. Chem Biol Drug Des. 2016;87(1):101\u201311.","journal-title":"Chem Biol Drug Des"},{"issue":"6","key":"293_CR14","doi-asserted-by":"publisher","first-page":"995","DOI":"10.3109\/14756366.2014.1003212","volume":"30","author":"F Mao","year":"2015","unstructured":"Mao F, Li J, Wei H, Huang L, Li X. Tacrine-propargylamine derivatives with improved acetylcholinesterase inhibitory activity and lower hepatotoxicity as a potential lead compound for the treatment of Alzheimer\u2019s disease. J Enzyme Inhib Med Chem. 2015;30(6):995\u20131001.","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"22","key":"293_CR15","doi-asserted-by":"publisher","first-page":"8985","DOI":"10.1021\/acs.jmedchem.5b01325","volume":"58","author":"E Nepovimova","year":"2015","unstructured":"Nepovimova E, Korabecny J, Dolezal R, Babkova K, Ondrejicek A, Jun D, et al. Tacrine-trolox hybrids: a novel class of centrally active, nonhepatotoxic multi-target-directed ligands exerting anticholinesterase and antioxidant activities with low in vivo toxicity. J Med Chem. 2015;58(22):8985\u20139003.","journal-title":"J Med Chem"},{"issue":"17","key":"293_CR16","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1016\/j.bmcl.2015.07.026","volume":"25","author":"Y Chen","year":"2015","unstructured":"Chen Y, Liu Z, Fu TM, Li W, Xu X, Sun HP. Discovery of new acetylcholinesterase inhibitors with small core structures through shape-based virtual screening. Bioorg Med Chem Lett. 2015;25(17):3442\u20136.","journal-title":"Bioorg Med Chem Lett."},{"key":"293_CR17","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.pnpbp.2017.01.003","volume":"75","author":"M Horak","year":"2017","unstructured":"Horak M, Holubova K, Nepovimova E, Krusek J, Kaniakova M, Korabecny J, et al. The pharmacology of tacrine at N-methyl-d-aspartate receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2017;75:54\u201362.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"293_CR18","doi-asserted-by":"publisher","first-page":"6412","DOI":"10.1038\/s41598-018-24501-0","volume":"8","author":"JW Arndt","year":"2018","unstructured":"Arndt JW, Qian F, Smith BA, Quan C, Kilambi KP, Bush MW, et al. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-beta. Sci Rep. 2018;8(1):6412.","journal-title":"Sci Rep"},{"issue":"7618","key":"293_CR19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces Abeta plaques in Alzheimer\u2019s disease. Nature. 2016;537(7618):50\u20136.","journal-title":"Nature"},{"key":"293_CR20","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1146\/annurev-med-042915-103753","volume":"68","author":"WV Graham","year":"2017","unstructured":"Graham WV, Bonito-Oliva A, Sakmar TP. Update on Alzheimer\u2019s disease therapy and prevention strategies. Annu Rev Med. 2017;68:413\u201330.","journal-title":"Annu Rev Med"},{"key":"293_CR21","doi-asserted-by":"crossref","unstructured":"Flores E, Pe\u00f1a-Ortega F. Amyloid \u03b2 Peptide-Induced Changes in Prefrontal Cortex Activity and Its Response to Hippocampal Input. Int J Pept.2017;1\u20139.","DOI":"10.1155\/2017\/7386809"},{"key":"293_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ejphar.2020.173554","volume":"887","author":"M Vaz","year":"2020","unstructured":"Vaz M, Silvestre S. Alzheimer\u2019s disease: Recent treatment strategies. Eur J Pharmacol. 2020;887:13.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"293_CR23","doi-asserted-by":"publisher","first-page":"247","DOI":"10.7861\/clinmedicine.16-3-247","volume":"16","author":"R Briggs","year":"2016","unstructured":"Briggs R, Kennelly SP, O\u2019Neill D. Drug treatments in Alzheimer\u2019s disease. Clin Med (Lond). 2016;16(3):247\u201353.","journal-title":"Clin Med (Lond)"},{"issue":"9","key":"293_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/ijms21093272","volume":"21","author":"MT Kabir","year":"2020","unstructured":"Kabir MT, Uddin MS, Mamun AA, Jeandet P, Aleya L, Mansouri RA, et al. Combination drug therapy for the management of Alzheimer\u2019s disease. Int J Mol Sci. 2020;21(9):23.","journal-title":"Int J Mol Sci"},{"key":"293_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1155\/2020\/5120230","volume":"2020","author":"S Maramai","year":"2020","unstructured":"Maramai S, Benchekroun M, Gabr MT, Yahiaoui S. Multitarget therapeutic strategies for Alzheimer\u2019s disease: review on emerging target combinations. Biomed Res Int. 2020;2020:27.","journal-title":"Biomed Res Int"},{"issue":"1","key":"293_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12952-017-0066-3","volume":"16","author":"S Hunter","year":"2017","unstructured":"Hunter S, Brayne C. Do anti-amyloid beta protein antibody cross reactivities confound Alzheimer disease research? J Negat Results Biomed. 2017;16(1):1.","journal-title":"J Negat Results Biomed."},{"issue":"6","key":"293_CR27","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1523\/JNEUROSCI.3266-15.2016","volume":"36","author":"H Oh","year":"2016","unstructured":"Oh H, Steffener J, Razlighi QR, Habeck C, Stern Y. \u03b2-Amyloid deposition is associated with decreased right prefrontal activation during task switching among cognitively normal elderly. J Neurosci. 2016;36(6):1962\u201370.","journal-title":"J Neurosci"},{"key":"293_CR28","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.ejmech.2015.08.039","volume":"121","author":"H Zeng","year":"2016","unstructured":"Zeng H, Wu X. Alzheimer\u2019s disease drug development based on computer-aided drug design. Eur J Med Chem. 2016;121:851\u201363.","journal-title":"Eur J Med Chem"},{"issue":"12","key":"293_CR29","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/cns.12472","volume":"21","author":"SQ Hu","year":"2015","unstructured":"Hu SQ, Wang R, Cui W, Mak SH, Li G, Hu YJ, et al. Dimeric bis (heptyl)-cognitin blocks Alzheimer\u2019s beta-amyloid neurotoxicity via the inhibition of abeta fibrils formation and disaggregation of preformed fibrils. CNS Neurosci Ther. 2015;21(12):953\u201361.","journal-title":"CNS Neurosci Ther"},{"issue":"5","key":"293_CR30","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1159\/000358875","volume":"60","author":"A Boutajangout","year":"2014","unstructured":"Boutajangout A, Wisniewski T. Tau-based therapeutic approaches for Alzheimer\u2019s disease - a mini-review. Gerontology. 2014;60(5):381\u20135.","journal-title":"Gerontology"},{"issue":"4","key":"293_CR31","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3109\/00207454.2013.831852","volume":"124","author":"M Obulesu","year":"2014","unstructured":"Obulesu M, Jhansilakshmi M. Neuroinflammation in Alzheimer\u2019s disease: an understanding of physiology and pathology. Int J Neurosci. 2014;124(4):227\u201335.","journal-title":"Int J Neurosci"},{"issue":"5","key":"293_CR32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1371\/journal.pone.0177044","volume":"12","author":"ML Haaksma","year":"2017","unstructured":"Haaksma ML, Vilela LR, Marengoni A, Calderon-Larranaga A, Leoutsakos JMS, Rikkert M, et al. Comorbidity and progression of late onset Alzheimer\u2019s disease: A systematic review. PLoS ONE. 2017;12(5):15.","journal-title":"PLoS ONE"},{"key":"293_CR33","doi-asserted-by":"publisher","first-page":"631770","DOI":"10.3389\/fnagi.2021.631770","volume":"13","author":"JA Santiago","year":"2021","unstructured":"Santiago JA, Potashkin JA. The impact of disease comorbidities in Alzheimer\u2019s disease. Front Aging Neurosci. 2021;13:631770.","journal-title":"Front Aging Neurosci."},{"key":"293_CR34","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.archger.2018.05.006","volume":"77","author":"C Bernardes","year":"2018","unstructured":"Bernardes C, Massano J, Freitas A. Hospital admissions 2000\u20132014: a retrospective analysis of 288 096 events in patients with dementia. Arch Gerontol Geriatr. 2018;77:150\u20137.","journal-title":"Arch Gerontol Geriatr"},{"issue":"2","key":"293_CR35","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.diabres.2013.11.002","volume":"103","author":"L Guariguata","year":"2014","unstructured":"Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103(2):137\u201349.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"293_CR36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/bpa.12655","volume":"29","author":"Y Chornenkyy","year":"2019","unstructured":"Chornenkyy Y, Wang WX, Wei A, Nelson PT. Alzheimer\u2019s disease and type 2 diabetes mellitus are distinct diseases with potential overlapping metabolic dysfunction upstream of observed cognitive decline. Brain Pathol. 2019;29(1):3\u201317.","journal-title":"Brain Pathol"},{"issue":"6","key":"293_CR37","doi-asserted-by":"publisher","first-page":"744","DOI":"10.4103\/2230-8210.167553","volume":"19","author":"F Chentli","year":"2015","unstructured":"Chentli F, Azzoug S, Mahgoun S. Diabetes mellitus in elderly. Indian J Endocrinol Metab. 2015;19(6):744\u201352.","journal-title":"Indian J Endocrinol Metab"},{"issue":"4","key":"293_CR38","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s11011-013-9406-2","volume":"28","author":"HT Yang","year":"2013","unstructured":"Yang HT, Sheen YJ, Kao CD, Chang CA, Hu YC, Lin JL. Association between the characteristics of metabolic syndrome and Alzheimer\u2019s disease. Metab Brain Dis. 2013;28(4):597\u2013604.","journal-title":"Metab Brain Dis"},{"issue":"1 Suppl","key":"293_CR39","first-page":"S26","volume":"10","author":"FG De Felice","year":"2014","unstructured":"De Felice FG, Lourenco MV, Ferreira ST. How does brain insulin resistance develop in Alzheimer\u2019s disease? Alzheimers Dement. 2014;10(1 Suppl):S26-32.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"293_CR40","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s40572-018-0176-1","volume":"5","author":"KC Paul","year":"2018","unstructured":"Paul KC, Jerrett M, Ritz B. Type 2 diabetes mellitus and Alzheimer\u2019s disease: overlapping biologic mechanisms and environmental risk factors. Curr Environ Health Rep. 2018;5(1):44\u201358.","journal-title":"Curr Environ Health Rep"},{"issue":"50","key":"293_CR41","doi-asserted-by":"publisher","first-page":"34472","DOI":"10.1074\/jbc.R114.601351","volume":"289","author":"Y Zhu","year":"2014","unstructured":"Zhu Y, Shan X, Yuzwa SA, Vocadlo DJ. The emerging link between O-GlcNAc and Alzheimer disease. J Biol Chem. 2014;289(50):34472\u201381.","journal-title":"J Biol Chem"},{"key":"293_CR42","doi-asserted-by":"crossref","unstructured":"Szablewski L. Glucose Transporters in Brain: In Health and in Alzheimer's Disease. Alzheimers Dis. 2017;55(4):1307\u201320.","DOI":"10.3233\/JAD-160841"},{"issue":"2","key":"293_CR43","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1590\/1980-57642016dn11-020002","volume":"11","author":"AM de Nazareth","year":"2017","unstructured":"de Nazareth AM. Type 2 diabetes mellitus in the pathophysiology of Alzheimer\u2019s disease. Dement Neuropsychol. 2017;11(2):105\u201313.","journal-title":"Dement Neuropsychol"},{"issue":"3","key":"293_CR44","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/1440-1681.12717","volume":"44","author":"BS Ashok","year":"2017","unstructured":"Ashok BS, Ajith TA, Sivanesan S. Hypoxia-inducible factors as neuroprotective agent in Alzheimer\u2019s disease. Clin Exp Pharmacol Physiol. 2017;44(3):327\u201334.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"2","key":"293_CR45","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3233\/JAD-170440","volume":"60","author":"R Karki","year":"2017","unstructured":"Karki R, Kodamullil AT, Hofmann-Apitius M. Comorbidity analysis between Alzheimer\u2019s disease and type 2 diabetes mellitus (T2DM) based on shared pathways and the role of T2DM drugs. J Alzheimers Dis. 2017;60(2):721\u201331.","journal-title":"J Alzheimers Dis"},{"key":"293_CR46","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3389\/fnagi.2018.00273","volume":"10","author":"N Ogama","year":"2018","unstructured":"Ogama N, Sakurai T, Kawashima S, Tanikawa T, Tokuda H, Satake S, et al. Postprandial hyperglycemia is associated with white matter hyperintensity and brain atrophy in older patients with type 2 diabetes mellitus. Front Aging Neurosci. 2018;10:273.","journal-title":"Front Aging Neurosci"},{"key":"293_CR47","doi-asserted-by":"publisher","first-page":"157.e11","DOI":"10.1016\/j.neurobiolaging.2017.11.013","volume":"64","author":"H Girard","year":"2018","unstructured":"Girard H, Potvin O, Nugent S, Dallaire-Theroux C, Cunnane S, Duchesne S. Faster progression from MCI to probable AD for carriers of a single-nucleotide polymorphism associated with type 2 diabetes. Neurobiol Aging. 2018;64:157.e11-.e17.","journal-title":"Neurobiol Aging."},{"issue":"4","key":"293_CR48","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/jnc.14256","volume":"144","author":"CM Nday","year":"2018","unstructured":"Nday CM, Eleftheriadou D, Jackson G. Shared pathological pathways of Alzheimer\u2019s disease with specific comorbidities: current perspectives and interventions. J Neurochem. 2018;144(4):360\u201389.","journal-title":"J Neurochem"},{"issue":"1\u20132","key":"293_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000345791","volume":"35","author":"BS Appleby","year":"2013","unstructured":"Appleby BS, Nacopoulos D, Milano N, Zhong K, Cummings JL. A review: treatment of Alzheimer\u2019s disease discovered in repurposed agents. Dement Geriatr Cogn Disord. 2013;35(1\u20132):1\u201322.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"293_CR50","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1155\/2016\/8501693","volume":"2016","author":"J Folch","year":"2016","unstructured":"Folch J, Petrov D, Ettcheto M, Abad S, Sanchez-Lopez E, Garcia ML, et al. Current research therapeutic strategies for Alzheimer\u2019s disease treatment. Neural Plast. 2016;2016:15.","journal-title":"Neural Plast"},{"issue":"2","key":"293_CR51","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000318845","volume":"30","author":"M Gold","year":"2010","unstructured":"Gold M, Alderton C, Zvartau-Hind M, Egginton S, Saunders AM, Irizarry M, et al. Rosiglitazone monotherapy in mild-to-moderate Alzheimer\u2019s disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord. 2010;30(2):131\u201346.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"5","key":"293_CR52","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1101\/cshperspect.a024075","volume":"7","author":"LM Smith","year":"2017","unstructured":"Smith LM, Strittmatter SM. binding sites for amyloid-beta oligomers and synaptic toxicity. Cold Spring Harb Perspect Med. 2017;7(5):18.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"9","key":"293_CR53","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1001\/jamaneurol.2020.1840","volume":"77","author":"S Craft","year":"2020","unstructured":"Craft S, Raman R, Chow TW, Rafii MS, Sun CK, Rissman RA, et al. Safety, efficacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and Alzheimer disease dementia a randomized clinical trial. JAMA Neurol. 2020;77(9):1099\u2013109.","journal-title":"JAMA Neurol"},{"key":"293_CR54","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/1179573520907397","volume":"12","author":"KG Yiannopoulou","year":"2020","unstructured":"Yiannopoulou KG, Papageorgiou SG. Current and future treatments in Alzheimer disease: an update. J Cent Nerv Syst Dis. 2020;12:12.","journal-title":"J Cent Nerv Syst Dis"},{"key":"293_CR55","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13063-019-3259-x","volume":"20","author":"GD Femminella","year":"2019","unstructured":"Femminella GD, Frangou E, Love SB, Busza G, Holmes C, Ritchie C, et al. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer\u2019s disease: study protocol for a randomised controlled trial (ELAD study). Trials. 2019;20:10.","journal-title":"Trials"},{"key":"293_CR56","doi-asserted-by":"publisher","first-page":"4981814","DOI":"10.1155\/2020\/4981814","volume":"2020","author":"Y Sun","year":"2020","unstructured":"Sun Y, Ma C, Sun H, Wang H, Peng W, Zhou Z, et al. Metabolism: a novel shared link between diabetes mellitus and Alzheimer\u2019s disease. J Diabetes Res. 2020;2020:4981814.","journal-title":"J Diabetes Res"},{"issue":"9765","key":"293_CR57","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S0140-6736(10)62038-7","volume":"377","author":"F Farzadfar","year":"2011","unstructured":"Farzadfar F, Finucane MM, Danaei G, Pelizzari PM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants. Lancet. 2011;377(9765):578\u201386.","journal-title":"Lancet."},{"issue":"12","key":"293_CR58","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1042\/CS20150351","volume":"129","author":"HK Dias","year":"2015","unstructured":"Dias HK, Brown CL, Polidori MC, Lip GY, Griffiths HR. LDL-lipids from patients with hypercholesterolaemia and Alzheimer\u2019s disease are inflammatory to microvascular endothelial cells: mitigation by statin intervention. Clin Sci (Lond). 2015;129(12):1195\u2013206.","journal-title":"Clin Sci (Lond)"},{"issue":"4","key":"293_CR59","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/jnc.12637","volume":"129","author":"WG Wood","year":"2014","unstructured":"Wood WG, Li L, Muller WE, Eckert GP. Cholesterol as a causative factor in Alzheimer\u2019s disease: a debatable hypothesis. J Neurochem. 2014;129(4):559\u201372.","journal-title":"J Neurochem"},{"issue":"1","key":"293_CR60","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00394-015-1053-4","volume":"56","author":"P Bahety","year":"2017","unstructured":"Bahety P, Van Nguyen TH, Hong Y, Zhang L, Chan ECY, Ee PLR. Understanding the cholesterol metabolism-perturbing effects of docosahexaenoic acid by gas chromatography-mass spectrometry targeted metabonomic profiling. Eur J Nutr. 2017;56(1):29\u201343.","journal-title":"Eur J Nutr"},{"key":"293_CR61","first-page":"1823","volume":"9","author":"Y Cheng","year":"2014","unstructured":"Cheng Y, Jin Y, Unverzagt FW, Su L, Yang L, Ma F, et al. The relationship between cholesterol and cognitive function is homocysteine-dependent. Clin Interv Aging. 2014;9:1823\u20139.","journal-title":"Clin Interv Aging"},{"issue":"12","key":"293_CR62","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/iub.1091","volume":"64","author":"R Ricciarelli","year":"2012","unstructured":"Ricciarelli R, Canepa E, Marengo B, Marinari UM, Poli G, Pronzato MA, et al. Cholesterol and Alzheimer\u2019s disease: a still poorly understood correlation. IUBMB Life. 2012;64(12):931\u20135.","journal-title":"IUBMB Life"},{"key":"293_CR63","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.cca.2016.02.024","volume":"456","author":"Z Xue-Shan","year":"2016","unstructured":"Xue-Shan Z, Juan P, Qi W, Zhong R, Li-Hong P, Zhi-Han T, et al. Imbalanced cholesterol metabolism in Alzheimer\u2019s disease. Clin Chim Acta. 2016;456:107\u201314.","journal-title":"Clin Chim Acta"},{"issue":"4","key":"293_CR64","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.mcn.2010.08.001","volume":"45","author":"C Ullrich","year":"2010","unstructured":"Ullrich C, Pirchl M, Humpel C. Hypercholesterolemia in rats impairs the cholinergic system and leads to memory deficits. Mol Cell Neurosci. 2010;45(4):408\u201317.","journal-title":"Mol Cell Neurosci"},{"key":"293_CR65","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.exger.2015.03.010","volume":"65","author":"M Ettcheto","year":"2015","unstructured":"Ettcheto M, Petrov D, Pedros I, de Lemos L, Pallas M, Alegret M, et al. Hypercholesterolemia and neurodegeneration. Comparison of hippocampal phenotypes in LDLr knockout and APPswe\/PS1dE9 mice. Exp Gerontol. 2015;65:69\u201378.","journal-title":"Exp Gerontol."},{"issue":"2","key":"293_CR66","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2174\/156720507780362047","volume":"4","author":"RA Whitmer","year":"2007","unstructured":"Whitmer RA, Gunderson EP, Quesenberry CP Jr, Zhou J, Yaffe K. Body mass index in midlife and risk of Alzheimer disease and vascular dementia. Curr Alzheimer Res. 2007;4(2):103\u20139.","journal-title":"Curr Alzheimer Res"},{"issue":"1\u20132","key":"293_CR67","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jns.2012.07.032","volume":"322","author":"RN Kalaria","year":"2012","unstructured":"Kalaria RN, Akinyemi R, Ihara M. Does vascular pathology contribute to Alzheimer changes? J Neurol Sci. 2012;322(1\u20132):141\u20137.","journal-title":"J Neurol Sci"},{"issue":"6","key":"293_CR68","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.pjnns.2016.07.002","volume":"50","author":"A Arslan","year":"2016","unstructured":"Arslan A, Tuzun FA, Arslan H, Demir H, Tamer S, Demir C, et al. The relationship between serum paraoxonase levels and carotid atherosclerotic plaque formation in Alzheimer\u2019s patients. Neurol Neurochir Pol. 2016;50(6):403\u20139.","journal-title":"Neurol Neurochir Pol"},{"issue":"Pt 12","key":"293_CR69","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1093\/brain\/aws271","volume":"135","author":"M Yarchoan","year":"2012","unstructured":"Yarchoan M, Xie SX, Kling MA, Toledo JB, Wolk DA, Lee EB, et al. Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. Brain. 2012;135(Pt 12):3749\u201356.","journal-title":"Brain"},{"issue":"12","key":"293_CR70","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1161\/STROKEAHA.112.672527","volume":"43","author":"CR Wendell","year":"2012","unstructured":"Wendell CR, Waldstein SR, Ferrucci L, O\u2019Brien RJ, Strait JB, Zonderman AB. Carotid atherosclerosis and prospective risk of dementia. Stroke. 2012;43(12):3319\u201324.","journal-title":"Stroke"},{"issue":"16","key":"293_CR71","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1212\/WNL.0000000000002590","volume":"86","author":"J Gutierrez","year":"2016","unstructured":"Gutierrez J, Honig L, Elkind MS, Mohr JP, Goldman J, Dwork AJ, et al. Brain arterial aging and its relationship to Alzheimer dementia. Neurology. 2016;86(16):1507\u201315.","journal-title":"Neurology"},{"issue":"2","key":"293_CR72","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/ana.22055","volume":"68","author":"H Dolan","year":"2010","unstructured":"Dolan H, Crain B, Troncoso J, Resnick SM, Zonderman AB, Obrien RJ. Atherosclerosis, dementia, and Alzheimer disease in the baltimore longitudinal study of aging cohort. Ann Neurol. 2010;68(2):231\u201340.","journal-title":"Ann Neurol"},{"issue":"9","key":"293_CR73","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.jacc.2014.12.035","volume":"65","author":"K Stamatelopoulos","year":"2015","unstructured":"Stamatelopoulos K, Sibbing D, Rallidis LS, Georgiopoulos G, Stakos D, Braun S, et al. Amyloid-beta (1\u201340) and the risk of death from cardiovascular causes in patients with coronary heart disease. J Am Coll Cardiol. 2015;65(9):904\u201316.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"293_CR74","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1385\/JMN:17:2:147","volume":"17","author":"DM Holtzman","year":"2001","unstructured":"Holtzman DM. Role of apoe\/Abeta interactions in the pathogenesis of Alzheimer\u2019s disease and cerebral amyloid angiopathy. J Mol Neurosci. 2001;17(2):147\u201355.","journal-title":"J Mol Neurosci"},{"issue":"9346","key":"293_CR75","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","volume":"360","author":"J Shepherd","year":"2002","unstructured":"Shepherd J, Blauw GJ, Murphy MB, Bollen E, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623\u201330.","journal-title":"Lancet"},{"issue":"9326","key":"293_CR76","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","volume":"360","author":"R Collins","year":"2002","unstructured":"Collins R, Armitage J, Parish S, Sleight P, Peto R. Heart protection study C. MRC\/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7\u201322.","journal-title":"Lancet."},{"key":"293_CR77","first-page":"47","volume":"1","author":"B McGuinness","year":"2016","unstructured":"McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev. 2016;1:47.","journal-title":"Cochrane Database Syst Rev"},{"key":"293_CR78","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13024-018-0299-8","volume":"13","author":"JQ Cao","year":"2018","unstructured":"Cao JQ, Hou JW, Ping J, Cai DM. Advances in developing novel therapeutic strategies for Alzheimer\u2019s disease. Mol Neurodegener. 2018;13:20.","journal-title":"Mol Neurodegener"},{"issue":"3","key":"293_CR79","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1159\/000503105","volume":"54","author":"TN Poly","year":"2020","unstructured":"Poly TN, Islam M, Walther BA, Yang HC, Wu CC, Lin MC, et al. Association between use of statin and risk of dementia: a meta-analysis of observational studies. Neuroepidemiology. 2020;54(3):214\u201326.","journal-title":"Neuroepidemiology"},{"key":"293_CR80","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41598-018-24248-8","volume":"8","author":"CS Chu","year":"2018","unstructured":"Chu CS, Tseng PT, Stubbs B, Chen TY, Tang CH, Li DJ, et al. Use of statins and the risk of dementia and mild cognitive impairment: A systematic review and meta-analysis. Sci Rep. 2018;8:12.","journal-title":"Sci Rep"},{"issue":"1","key":"293_CR81","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13195-017-0262-x","volume":"9","author":"JM Gabin","year":"2017","unstructured":"Gabin JM, Tambs K, Saltvedt I, Sund E, Holmen J. Association between blood pressure and Alzheimer disease measured up to 27 years prior to diagnosis: the HUNT Study. Alzheimers Res Ther. 2017;9(1):37.","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"293_CR82","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1161\/STROKEAHA.115.009010","volume":"47","author":"A Viswanathan","year":"2016","unstructured":"Viswanathan A, Greenberg SM, Scheltens P. Role of vascular disease in Alzheimer-like progressive cognitive impairment. Stroke. 2016;47(2):577\u201380.","journal-title":"Stroke"},{"issue":"5","key":"293_CR83","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/ana.25071","volume":"82","author":"P Vemuri","year":"2017","unstructured":"Vemuri P, Lesnick TG, Przybelski SA, Knopman DS, Lowe VJ, Graff-Radford J, et al. Age, vascular health, and Alzheimer disease biomarkers in an elderly sample. Ann Neurol. 2017;82(5):706\u201318.","journal-title":"Ann Neurol"},{"issue":"1","key":"293_CR84","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1161\/HYPERTENSIONAHA.114.04257","volume":"65","author":"E Thorin","year":"2015","unstructured":"Thorin E. Hypertension and Alzheimer disease: another brick in the wall of awareness. Hypertension. 2015;65(1):36\u20138.","journal-title":"Hypertension"},{"issue":"2","key":"293_CR85","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/ajh.2009.212","volume":"23","author":"M Nagai","year":"2010","unstructured":"Nagai M, Hoshide S, Kario K. Hypertension and dementia. Am J Hypertens. 2010;23(2):116\u201324.","journal-title":"Am J Hypertens"},{"issue":"2","key":"293_CR86","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s10571-015-0285-4","volume":"36","author":"E Hamel","year":"2016","unstructured":"Hamel E, Royea J, Ongali B, Tong XK. Neurovascular and cognitive failure in Alzheimer\u2019s disease: benefits of cardiovascular therapy. Cell Mol Neurobiol. 2016;36(2):219\u201332.","journal-title":"Cell Mol Neurobiol"},{"issue":"1","key":"293_CR87","doi-asserted-by":"publisher","first-page":"8","DOI":"10.23736\/S0031-0808.18.03360-8","volume":"60","author":"A Marfany","year":"2018","unstructured":"Marfany A, Sierra C, Camafort M, Domenech M, Coca A. High blood pressure, Alzheimer disease and antihypertensive treatment. Panminerva Med. 2018;60(1):8\u201316.","journal-title":"Panminerva Med"},{"issue":"6","key":"293_CR88","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1161\/HYP.0000000000000053","volume":"68","author":"C Iadecola","year":"2016","unstructured":"Iadecola C, Yaffe K, Biller J, Bratzke LC, Faraci FM, Gorelick PB, et al. Impact of hypertension on cognitive function: a scientific statement from the american heart association. Hypertension. 2016;68(6):e67\u201394.","journal-title":"Hypertension"},{"issue":"9","key":"293_CR89","doi-asserted-by":"publisher","first-page":"e1002660","DOI":"10.1371\/journal.pmed.1002660","volume":"15","author":"B Lawlor","year":"2018","unstructured":"Lawlor B, Segurado R. Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. PLoS Med. 2018;15(9):e1002660.","journal-title":"PLoS Med."},{"issue":"1","key":"293_CR90","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.brainres.2003.11.061","volume":"999","author":"D Paris","year":"2004","unstructured":"Paris D, Quadros A, Humphrey J, Patel N, Crescentini R, Crawford F, et al. Nilvadipine antagonizes both A beta vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice. Brain Res. 2004;999(1):53\u201361.","journal-title":"Brain Res"},{"issue":"3\u20134","key":"293_CR91","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2119\/molmed.2010.00180","volume":"17","author":"D Paris","year":"2011","unstructured":"Paris D, Bachmeier C, Patel N, Quadros A, Volmar CH, Laporte V, et al. Selective antihypertensive dihydropyridines lower a beta accumulation by targeting both the production and the clearance of a beta across the blood-brain barrier. Mol Med. 2011;17(3\u20134):149\u201362.","journal-title":"Mol Med"},{"issue":"9","key":"293_CR92","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1371\/journal.pmed.1002660","volume":"15","author":"B Lawlor","year":"2018","unstructured":"Lawlor B, Segurado R, Kennelly S, Rikkert M, Howard R, Pasquier F, et al. Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. PLoS Med. 2018;15(9):20.","journal-title":"PLoS Med"},{"issue":"2","key":"293_CR93","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1161\/HYPERTENSIONAHA.119.12892","volume":"74","author":"DLK de Jong","year":"2019","unstructured":"de Jong DLK, de Heus RAA, Rijpma A, Donders R, Rikkert M, Gunther M, et al. Effects of nilvadipine on cerebral blood flow in patients with Alzheimer disease a randomized trial. Hypertension. 2019;74(2):413\u201320.","journal-title":"Hypertension"},{"key":"293_CR94","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fneur.2020.00149","volume":"11","author":"L Abdullah","year":"2020","unstructured":"Abdullah L, Crawford F, Tsolaki M, Borjesson-Hanson A, Rikkert MO, Pasquier F, et al. The influence of baseline Alzheimer\u2019s disease severity on cognitive decline and CSF biomarkers in the NILVAD trial. Front Neurol. 2020;11:13.","journal-title":"Front Neurol"},{"key":"293_CR95","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.cct.2019.02.007","volume":"79","author":"AN Szabo-Reed","year":"2019","unstructured":"Szabo-Reed AN, Vidoni E, Binder EF, Burns J, Cullum CM, Gahan WP, et al. Rationale and methods for a multicenter clinical trial assessing exercise and intensive vascular risk reduction in preventing dementia (rrAD Study). Contemp Clin Trials. 2019;79:44\u201354.","journal-title":"Contemp Clin Trials"},{"issue":"1","key":"293_CR96","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3233\/JAD-2012-120763","volume":"32","author":"W Wharton","year":"2012","unstructured":"Wharton W, Stein JH, Korcarz C, Sachs J, Olson SR, Zetterberg H, et al. The effects of ramipril in individuals at risk for Alzheimer\u2019s disease: results of a pilot clinical trial. J Alzheimers Dis. 2012;32(1):147\u201356.","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"293_CR97","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3233\/JAD-2011-110347","volume":"26","author":"NM Davies","year":"2011","unstructured":"Davies NM, Kehoe PG, Ben-Shlomo Y, Martin RM. Associations of anti-hypertensive treatments with Alzheimer\u2019s disease, vascular dementia, and other dementias. J Alzheimers Dis. 2011;26(4):699\u2013708.","journal-title":"J Alzheimers Dis"},{"issue":"9","key":"293_CR98","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nrn3983","volume":"16","author":"FK Wiseman","year":"2015","unstructured":"Wiseman FK, Al-Janabi T, Hardy J, Karmiloff-Smith A, Nizetic D, Tybulewicz VL, et al. A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat Rev Neurosci. 2015;16(9):564\u201374.","journal-title":"Nat Rev Neurosci"},{"key":"293_CR99","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.freeradbiomed.2016.10.508","volume":"111","author":"E Barone","year":"2017","unstructured":"Barone E, Head E, Butterfield DA, Perluigi M. HNE-modified proteins in Down syndrome: involvement in development of Alzheimer disease neuropathology. Free Radic Biol Med. 2017;111:262\u20139.","journal-title":"Free Radic Biol Med"},{"issue":"8","key":"293_CR100","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.jalz.2019.04.010","volume":"15","author":"RS Mahla","year":"2019","unstructured":"Mahla RS. Down syndrome cognitive marker\u2019s significance in Alzheimer\u2019s disease and dementia management. Alzheimers Dement. 2019;15(8):1117\u20138.","journal-title":"Alzheimers Dement"},{"key":"293_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2017.10.374","volume":"114","author":"DA Butterfield","year":"2018","unstructured":"Butterfield DA, Perluigi M. Down syndrome: From development to adult life to Alzheimer disease. Free Radic Biol Med. 2018;114:1\u20132.","journal-title":"Free Radic Biol Med"},{"key":"293_CR102","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.nicl.2016.06.001","volume":"11","author":"AL Lin","year":"2016","unstructured":"Lin AL, Powell D, Caban-Holt A, Jicha G, Robertson W, Gold BT, et al. (1)H-MRS metabolites in adults with Down syndrome: Effects of dementia. Neuroimage Clin. 2016;11:728\u201335.","journal-title":"Neuroimage Clin"},{"key":"293_CR103","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.freeradbiomed.2017.10.341","volume":"114","author":"XQ Chen","year":"2018","unstructured":"Chen XQ, Sawa M, Mobley WC. Dysregulation of neurotrophin signaling in the pathogenesis of Alzheimer disease and of Alzheimer disease in down syndrome. Free Radic Biol Med. 2018;114:52\u201361.","journal-title":"Free Radic Biol Med"},{"issue":"5","key":"293_CR104","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/mgg3.430","volume":"6","author":"O Sauna-Aho","year":"2018","unstructured":"Sauna-Aho O, Bjelogrlic-Laakso N. Signs indicating dementia in Down, williams and fragile X syndromes. Mol Genet Genomic Med. 2018;6(5):855\u201360.","journal-title":"Mol Genet Genomic Med"},{"key":"293_CR105","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.freeradbiomed.2014.08.006","volume":"76","author":"G Cenini","year":"2014","unstructured":"Cenini G, Fiorini A, Sultana R, Perluigi M, Cai J, Klein JB, et al. An investigation of the molecular mechanisms engaged before and after the development of Alzheimer disease neuropathology in Down syndrome: a proteomics approach. Free Radic Biol Med. 2014;76:89\u201395.","journal-title":"Free Radic Biol Med"},{"issue":"6","key":"293_CR106","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jalz.2018.01.002","volume":"14","author":"AD Cohen","year":"2018","unstructured":"Cohen AD, McDade E, Christian B, Price J, Mathis C, Klunk W, et al. Early striatal amyloid deposition distinguishes Down syndrome and autosomal dominant Alzheimer\u2019s disease from late-onset amyloid deposition. Alzheimers Dement. 2018;14(6):743\u201350.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"293_CR107","first-page":"353","volume":"1","author":"E Head","year":"2012","unstructured":"Head E, Powell D, Gold BT, Schmitt FA. Alzheimer\u2019s disease in Down syndrome. Eur J Neurodegener Dis. 2012;1(3):353\u201364.","journal-title":"Eur J Neurodegener Dis"},{"issue":"3","key":"293_CR108","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/nan.12406","volume":"44","author":"I Milenkovic","year":"2018","unstructured":"Milenkovic I, Jarc J, Dassler E, Aronica E, Iyer A, Adle-Biassette H, et al. The physiological phosphorylation of tau is critically changed in fetal brains of individuals with Down syndrome. Neuropathol Appl Neurobiol. 2018;44(3):314\u201327.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"1","key":"293_CR109","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.stemcr.2018.05.004","volume":"11","author":"DA Ovchinnikov","year":"2018","unstructured":"Ovchinnikov DA, Korn O, Virshup I, Wells CA, Wolvetang EJ. The impact of APP on Alzheimer-like pathogenesis and gene expression in Down syndrome iPSC-derived neurons. Stem Cell Reports. 2018;11(1):32\u201342.","journal-title":"Stem Cell Reports"},{"issue":"1","key":"293_CR110","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2174\/1567205012666150921095505","volume":"13","author":"ED Hamlett","year":"2016","unstructured":"Hamlett ED, Boger HA, Ledreux A, Kelley CM, Mufson EJ, Falangola MF, et al. Cognitive impairment, neuroimaging, and Alzheimer neuropathology in mouse models of Down syndrome. Curr Alzheimer Res. 2016;13(1):35\u201352.","journal-title":"Curr Alzheimer Res"},{"issue":"10","key":"293_CR111","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/S1474-4422(18)30285-0","volume":"17","author":"J Fortea","year":"2018","unstructured":"Fortea J, Carmona-Iragui M, Benejam B, Fernandez S, Videla L, Barroeta I, et al. Plasma and CSF biomarkers for the diagnosis of Alzheimer\u2019s disease in adults with Down syndrome: a cross-sectional study. Lancet Neurol. 2018;17(10):860\u20139.","journal-title":"Lancet Neurol"},{"issue":"4","key":"293_CR112","doi-asserted-by":"publisher","first-page":"154","DOI":"10.25100\/cm.v45i4.1640","volume":"45","author":"JC Montoya","year":"2014","unstructured":"Montoya JC, Fajardo D, Pena A, Sanchez A, Dominguez MC, Satizabal JM, et al. Global differential expression of genes located in the Down syndrome critical region in normal human brain. Colomb Med. 2014;45(4):154\u201361.","journal-title":"Colomb Med"},{"issue":"1","key":"293_CR113","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/ph12010041","volume":"12","author":"MA Maia","year":"2019","unstructured":"Maia MA, Sousa E. BACE-1 and \u03b3-secretase as therapeutic targets for Alzheimer\u2019s disease. Pharmaceuticals (Basel). 2019;12(1):41.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"31","key":"293_CR114","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.2174\/1568026618666180112161406","volume":"17","author":"A Rampa","year":"2017","unstructured":"Rampa A, Gobbi S, Concetta Di Martino RM, Belluti F, Bisi A. Dual BACE-1\/GSK-3beta inhibitors to combat Alzheimer\u2019s disease: a focused review. Curr Top Med Chem. 2017;17(31):3361\u20139.","journal-title":"Curr Top Med Chem."},{"issue":"3","key":"293_CR115","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/dneu.22556","volume":"78","author":"J Sun","year":"2018","unstructured":"Sun J, Roy S. The physical approximation of APP and BACE-1: A key event in Alzheimer\u2019s disease pathogenesis. Dev Neurobiol. 2018;78(3):340\u20137.","journal-title":"Dev Neurobiol"},{"key":"293_CR116","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1742-2094-10-84","volume":"10","author":"DM Wilcock","year":"2013","unstructured":"Wilcock DM, Griffin WS. Down\u2019s syndrome, neuroinflammation, and Alzheimer neuropathogenesis. J Neuroinflammation. 2013;10:84.","journal-title":"J Neuroinflammation"},{"key":"293_CR117","doi-asserted-by":"publisher","first-page":"724904","DOI":"10.1155\/2012\/724904","volume":"2012","author":"M Perluigi","year":"2012","unstructured":"Perluigi M, Butterfield DA. Oxidative stress and Down syndrome: a route toward alzheimer-like dementia. Curr Gerontol Geriatr Res. 2012;2012:724904.","journal-title":"Curr Gerontol Geriatr Res."},{"key":"293_CR118","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3389\/fnagi.2014.00136","volume":"6","author":"N Malakooti","year":"2014","unstructured":"Malakooti N, Pritchard MA, Adlard PA, Finkelstein DI. Role of metal ions in the cognitive decline of Down syndrome. Front Aging Neurosci. 2014;6:136.","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"293_CR119","first-page":"69","volume":"21","author":"A Klosowska","year":"2017","unstructured":"Klosowska A, Cwiklinska A, Kuchta A, Berlinska A, Jankowski M, Wierzba J. Down syndrome, increased risk of dementia and lipid disturbances. Dev Period Med. 2017;21(1):69\u201373.","journal-title":"Dev Period Med"},{"key":"293_CR120","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3389\/fnagi.2018.00191","volume":"10","author":"E Head","year":"2018","unstructured":"Head E, Powell DK, Schmitt FA. Metabolic and vascular imaging biomarkers in Down syndrome provide unique insights into brain aging and alzheimer disease pathogenesis. Front Aging Neurosci. 2018;10:191.","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"293_CR121","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s40478-017-0499-4","volume":"5","author":"E Head","year":"2017","unstructured":"Head E, Phelan MJ, Doran E, Kim RC, Poon WW, Schmitt FA, et al. Cerebrovascular pathology in Down syndrome and Alzheimer disease. Acta Neuropathol Commun. 2017;5(1):93.","journal-title":"Acta Neuropathol Commun"},{"key":"293_CR122","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3389\/fnbeh.2015.00268","volume":"9","author":"XY Choong","year":"2015","unstructured":"Choong XY, Tosh JL, Pulford LJ, Fisher EM. Dissecting Alzheimer disease in Down syndrome using mouse models. Front Behav Neurosci. 2015;9:268.","journal-title":"Front Behav Neurosci"},{"issue":"4","key":"293_CR123","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/j.1365-2788.2010.01262.x","volume":"54","author":"S Lanfranchi","year":"2010","unstructured":"Lanfranchi S, Jerman O, Dal Pont E, Alberti A, Vianello R. Executive function in adolescents with Down syndrome. J Intellect Disabil Res. 2010;54(4):308\u201319.","journal-title":"J Intellect Disabil Res"},{"key":"293_CR124","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.yebeh.2016.12.014","volume":"68","author":"T Gholipour","year":"2017","unstructured":"Gholipour T, Mitchell S, Sarkis RA, Chemali Z. The clinical and neurobehavioral course of Down syndrome and dementia with or without new-onset epilepsy. Epilepsy Behav. 2017;68:11\u20136.","journal-title":"Epilepsy Behav"},{"issue":"12","key":"293_CR125","doi-asserted-by":"publisher","first-page":"e1564","DOI":"10.4088\/JCP.15m10617","volume":"77","author":"EA Weamer","year":"2016","unstructured":"Weamer EA, DeMichele-Sweet MA, Cloonan YK, Lopez OL, Sweet RA. Incident psychosis in subjects with mild cognitive impairment or Alzheimer\u2019s disease. J Clin Psychiatry. 2016;77(12):e1564\u20139.","journal-title":"J Clin Psychiatry"},{"key":"293_CR126","doi-asserted-by":"publisher","first-page":"e2751","DOI":"10.1590\/1518-8345.0580.2751","volume":"24","author":"LB Storti","year":"2016","unstructured":"Storti LB, Quintino DT, Silva NM, Kusumota L, Marques S. Neuropsychiatric symptoms of the elderly with Alzheimer\u2019s disease and the family caregivers\u2019 distress. Rev Lat Am Enfermagem. 2016;24:e2751.","journal-title":"Rev Lat Am Enfermagem."},{"issue":"1","key":"293_CR127","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/WAD.0000000000000161","volume":"31","author":"DP Devanand","year":"2017","unstructured":"Devanand DP, Pelton GH, D\u2019Antonio K, Strickler JG, Kreisl WC, Noble J, et al. Low-dose lithium treatment for agitation and psychosis in Alzheimer disease and frontotemporal dementia: a case series. Alzheimer Dis Assoc Disord. 2017;31(1):73\u20135.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"1","key":"293_CR128","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/ajmg.b.32413","volume":"174","author":"C Shah","year":"2017","unstructured":"Shah C, DeMichele-Sweet MA, Sweet RA. Genetics of psychosis of Alzheimer disease. Am J Med Genet B Neuropsychiatr Genet. 2017;174(1):27\u201335.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"issue":"4","key":"293_CR129","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/mp.2017.81","volume":"23","author":"MAA DeMichele-Sweet","year":"2018","unstructured":"DeMichele-Sweet MAA, Weamer EA, Klei L, Vrana DT. Genetic risk for schizophrenia and psychosis in Alzheimer disease. Mol Psychiatry. 2018;23(4):963\u201372.","journal-title":"Mol Psychiatry"},{"issue":"6","key":"293_CR130","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1001\/jamapsychiatry.2018.0482","volume":"75","author":"J Koppel","year":"2018","unstructured":"Koppel J, Sousa A, Gordon ML, Giliberto L, Christen E, Davies P. Association between psychosis in elderly patients with Alzheimer disease and impaired social cognition. JAMA Psychiat. 2018;75(6):652\u20133.","journal-title":"JAMA Psychiat"},{"key":"293_CR131","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.2147\/NDT.S60837","volume":"10","author":"J Koppel","year":"2014","unstructured":"Koppel J, Greenwald BS. Optimal treatment of Alzheimer\u2019s disease psychosis: challenges and solutions. Neuropsychiatr Dis Treat. 2014;10:2253\u201362.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"11","key":"293_CR132","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/gps.1397","volume":"20","author":"J Kennedy","year":"2005","unstructured":"Kennedy J, Deberdt W, Siegal A, Micca J, Degenhardt E, Ahl J, et al. Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer\u2019s dementia. Int J Geriatr Psychiatry. 2005;20(11):1020\u20137.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"4","key":"293_CR133","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1517\/14656566.2013.764989","volume":"14","author":"PP De Deyn","year":"2013","unstructured":"De Deyn PP, Drenth AFJ, Kremer BP, Voshaar RCO, Van Dam D. Aripiprazole in the treatment of Alzheimer\u2019s disease. Expert Opin Pharmacother. 2013;14(4):459\u201374.","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"293_CR134","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1176\/appi.ajp.2011.08121844","volume":"168","author":"CLP Vigen","year":"2011","unstructured":"Vigen CLP, Mack WJ, Keefe RSE, Sano M, Sultzer DL, Stroup TS, et al. Cognitive Effects of atypical antipsychotic medications in patients with Alzheimer\u2019s disease: outcomes from CATIE-AD. Am J Psychiatry. 2011;168(8):831\u20139.","journal-title":"Am J Psychiatry"},{"issue":"5","key":"293_CR135","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.apnu.2018.03.008","volume":"32","author":"E Mess","year":"2018","unstructured":"Mess E, Witkowicz M, Ornat M, Sielski P, Klaszczyk T. Evaluation of depression in patients with Alzheimer\u2019s disease according to the location of medical care. Arch Psychiatr Nurs. 2018;32(5):688\u201394.","journal-title":"Arch Psychiatr Nurs"},{"issue":"4","key":"293_CR136","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tins.2018.01.010","volume":"41","author":"D Weinshenker","year":"2018","unstructured":"Weinshenker D. Long road to ruin: noradrenergic dysfunction in neurodegenerative disease. Trends Neurosci. 2018;41(4):211\u201323.","journal-title":"Trends Neurosci"},{"issue":"5","key":"293_CR137","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00401-020-02248-1","volume":"141","author":"BJ Matchett","year":"2021","unstructured":"Matchett BJ, Grinberg LT, Theofilas P, Murray ME. The mechanistic link between selective vulnerability of the locus coeruleus and neurodegeneration in Alzheimer\u2019s disease. Acta Neuropathol. 2021;141(5):631\u201350.","journal-title":"Acta Neuropathol"},{"issue":"4","key":"293_CR138","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s00213-018-5137-8","volume":"236","author":"M Amani","year":"2019","unstructured":"Amani M, Shokouhi G, Salari AA. Minocycline prevents the development of depression-like behavior and hippocampal inflammation in a rat model of Alzheimer\u2019s disease. Psychopharmacology (Berl). 2019;236(4):1281\u201392.","journal-title":"Psychopharmacology (Berl)."},{"issue":"11","key":"293_CR139","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.7150\/ijbs.25000","volume":"14","author":"Q-E Zhang","year":"2018","unstructured":"Zhang Q-E, Ling S, Li P, Zhang S, Ng CH, Ungvari GS, et al. The association between urinary Alzheimer-associated neuronal thread protein and cognitive impairment in late-life depression: a controlled pilot study. Int J Biol Sci. 2018;14(11):1497\u2013502.","journal-title":"Int J Biol Sci"},{"issue":"2","key":"293_CR140","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1159\/000489847","volume":"8","author":"CG Schipke","year":"2018","unstructured":"Schipke CG, De Vos A, Fuentes M, Jacobs D, Vanmechelen E, Peters O. Neurogranin and BACE1 in CSF as potential biomarkers differentiating depression with cognitive deficits from early Alzheimer\u2019s disease: a pilot study. Dement Geriatr Cogn Dis Extra. 2018;8(2):277\u201389.","journal-title":"Dement Geriatr Cogn Dis Extra"},{"key":"293_CR141","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3389\/fpsyt.2018.00561","volume":"9","author":"C Madeira","year":"2018","unstructured":"Madeira C, Vargas-Lopes C, Brand\u00e3o CO, Reis T, Laks J, Panizzutti R, et al. Elevated glutamate and glutamine levels in the Cerebrospinal fluid of patients with probable Alzheimer\u2019s disease and depression. Front Psychiatry. 2018;9:561.","journal-title":"Front Psychiatry"},{"issue":"1","key":"293_CR142","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0301-0082(00)00067-8","volume":"65","author":"NC Danbolt","year":"2001","unstructured":"Danbolt NC. Glutamate uptake. Prog Neurobiol. 2001;65(1):1\u2013105.","journal-title":"Prog Neurobiol"},{"issue":"4","key":"293_CR143","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3233\/JAD-160763","volume":"57","author":"R Wang","year":"2017","unstructured":"Wang R, Reddy PH. Role of glutamate and NMDA receptors in Alzheimer\u2019s disease. J Alzheimers Dis. 2017;57(4):1041\u20138.","journal-title":"J Alzheimers Dis"},{"issue":"9","key":"293_CR144","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.3390\/molecules23092375","volume":"23","author":"H Xu","year":"2018","unstructured":"Xu H, Wang Z, Zhu L, Sui Z, Bi W, Liu R, et al. Targeted neurotransmitters profiling identifies metabolic signatures in rat brain by LC-MS\/MS: application in insomnia, depression and Alzheimer\u2019s disease. Molecules. 2018;23(9):2375.","journal-title":"Molecules"},{"issue":"1","key":"293_CR145","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4103\/1673-5374.264445","volume":"15","author":"B Mdawar","year":"2020","unstructured":"Mdawar B, Ghossoub E, Khoury R. Selective serotonin reuptake inhibitors and Alzheimer\u2019s disease. Neural Regen Res. 2020;15(1):41\u20136.","journal-title":"Neural Regen Res"},{"key":"293_CR146","doi-asserted-by":"crossref","unstructured":"Van Dam D, Vermeiren Y, Dekker AD, Naude PJ, Deyn PP. Neuropsychiatric Disturbances in Alzheimer's Disease: What Have We Learned from Neuropathological Studies? Curr Alzheimer Res. 2016;13(10):1145\u201364.","DOI":"10.2174\/1567205013666160502123607"},{"key":"293_CR147","unstructured":"Kisby B, Jarrell JT, Agar ME, Cohen DS, Rosin ER, Cahill CM, et al. Alzheimer's disease and its potential alternative therapeutics. J Alzheimers Dis Parkinsonism. 2019;9(5)."},{"issue":"7","key":"293_CR148","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1001\/jama.2014.93","volume":"311","author":"AP Porsteinsson","year":"2014","unstructured":"Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, et al. Effect of citalopram on agitation in Alzheimer disease The CitAD randomized clinical trial. JAMA. 2014;311(7):682\u201391.","journal-title":"JAMA"},{"issue":"5","key":"293_CR149","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1192\/bjp.bp.110.080044","volume":"198","author":"OV Forlenza","year":"2011","unstructured":"Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry. 2011;198(5):351\u20136.","journal-title":"Br J Psychiatry"},{"issue":"5","key":"293_CR150","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1192\/bjp.2019.76","volume":"215","author":"OV Forlenza","year":"2019","unstructured":"Forlenza OV, Radanovic M, Talib LL, Gattaz WF. Clinical and biological effects of long-term lithium treatment in older adults with amnestic mild cognitive impairment: randomised clinical trial. Br J Psychiatry. 2019;215(5):668\u201374.","journal-title":"Br J Psychiatry"},{"issue":"4","key":"293_CR151","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1590\/s1679-45082011ao2145","volume":"9","author":"EF Camargos","year":"2011","unstructured":"Camargos EF, Pandolfi MB, Dias MP, Quintas JL, Guimaraes RM, Nobrega OT. Incidence of sleep disorders in patients with Alzheimer disease. Einstein (Sao Paulo). 2011;9(4):461\u20135.","journal-title":"Einstein (Sao Paulo)"},{"issue":"3","key":"293_CR152","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s12603-010-0052-7","volume":"14","author":"S Bombois","year":"2010","unstructured":"Bombois S, Derambure P, Pasquier F, Monaca C. Sleep disorders in aging and dementia. J Nutr Health Aging. 2010;14(3):212\u20137.","journal-title":"J Nutr Health Aging"},{"key":"293_CR153","doi-asserted-by":"crossref","unstructured":"Ju YS, Videnovic A, Vaughn BV. Comorbid Sleep Disturbances in Neurologic Disorders. Continuum (Minneap Minn). 2017;23(4, Sleep Neurology):1117\u201331.","DOI":"10.1212\/CON.0000000000000501"},{"key":"293_CR154","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/NSS.S76706","volume":"8","author":"E Urrestarazu","year":"2016","unstructured":"Urrestarazu E, Iriarte J. Clinical management of sleep disturbances in Alzheimer\u2019s disease: current and emerging strategies. Nat Sci Sleep. 2016;8:21\u201333.","journal-title":"Nat Sci Sleep"},{"key":"293_CR155","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.brainresbull.2020.04.009","volume":"160","author":"FS Giorgi","year":"2020","unstructured":"Giorgi FS, Saccaro LF, Busceti CL, Biagioni F, Fornai F. Epilepsy and Alzheimer\u2019s disease: potential mechanisms for an association. Brain Res Bull. 2020;160:107\u201320.","journal-title":"Brain Res Bull"},{"key":"293_CR156","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.seizure.2018.03.014","volume":"58","author":"T Rauramaa","year":"2018","unstructured":"Rauramaa T, Saxlin A, Lohvansuu K, Alafuzoff I, Pitk\u00e4nen A, Soininen H. Epilepsy in neuropathologically verified Alzheimer\u2019s disease. Seizure. 2018;58:9\u201312.","journal-title":"Seizure"},{"issue":"4","key":"293_CR157","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/j.1755-5949.2011.00251.x","volume":"18","author":"D Friedman","year":"2012","unstructured":"Friedman D, Honig LS, Scarmeas N. Seizures and epilepsy in Alzheimer\u2019s disease. CNS Neurosci Ther. 2012;18(4):285\u201394.","journal-title":"CNS Neurosci Ther"},{"issue":"7","key":"293_CR158","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1080\/14737175.2019.1629289","volume":"19","author":"G Powell","year":"2019","unstructured":"Powell G, Ziso B, Larner AJ. The overlap between epilepsy and Alzheimer\u2019s disease and the consequences for treatment. Expert Rev Neurother. 2019;19(7):653\u201361.","journal-title":"Expert Rev Neurother"},{"issue":"1","key":"293_CR159","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1590\/S1980-57642014DN81000010","volume":"8","author":"DDC Miranda","year":"2014","unstructured":"Miranda DDC, Brucki SMD. Epilepsy in patients with Alzheimer\u2019s disease: A systematic review. Dement Neuropsychol. 2014;8(1):66\u201371.","journal-title":"Dement Neuropsychol"},{"issue":"10","key":"293_CR160","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1021\/acschemneuro.9b00460","volume":"10","author":"YN Paudel","year":"2019","unstructured":"Paudel YN, Angelopoulou E, Jones NC, O\u2019Brien TJ, Kwan P, Piperi C, et al. Tau Related pathways as a connecting link between epilepsy and Alzheimer\u2019s disease. ACS Chem Neurosci. 2019;10(10):4199\u2013212.","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"293_CR161","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1684\/epd.2016.0808","volume":"18","author":"N Nicastro","year":"2016","unstructured":"Nicastro N, Assal F, Seeck M. From here to epilepsy: the risk of seizure in patients with Alzheimer\u2019s disease. Epileptic Disord. 2016;18(1):1\u201312.","journal-title":"Epileptic Disord"},{"issue":"3","key":"293_CR162","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.3233\/JAD-170925","volume":"63","author":"A Horv\u00e1th","year":"2018","unstructured":"Horv\u00e1th A, Sz\u0171cs A, Hidasi Z, Csukly G, Barcs G, Kamondi A. Prevalence, semiology, and risk factors of epilepsy in Alzheimer\u2019s disease: an ambulatory EEG study. J Alzheimers Dis. 2018;63(3):1045\u201354.","journal-title":"J Alzheimers Dis"},{"issue":"11","key":"293_CR163","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1523\/JNEUROSCI.5215-08.2009","volume":"29","author":"R Minkeviciene","year":"2009","unstructured":"Minkeviciene R, Rheims S, Dobszay MB, Zilberter M, Hartikainen J, F\u00fcl\u00f6p L, et al. Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci. 2009;29(11):3453\u201362.","journal-title":"J Neurosci"},{"issue":"4","key":"293_CR164","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1001\/archneurol.2009.15","volume":"66","author":"JJ Palop","year":"2009","unstructured":"Palop JJ, Mucke L. Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol. 2009;66(4):435\u201340.","journal-title":"Arch Neurol"},{"key":"293_CR165","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.neurobiolaging.2018.09.006","volume":"73","author":"C Costa","year":"2019","unstructured":"Costa C, Romoli M, Liguori C, Farotti L, Eusebi P, Bedetti C, et al. Alzheimer\u2019s disease and late-onset epilepsy of unknown origin: two faces of beta amyloid pathology. Neurobiol Aging. 2019;73:61\u20137.","journal-title":"Neurobiol Aging"},{"key":"293_CR166","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.neurobiolaging.2016.08.025","volume":"48","author":"C Costa","year":"2016","unstructured":"Costa C, Parnetti L, D\u2019Amelio M, Tozzi A, Tantucci M, Romigi A, et al. Epilepsy, amyloid-\u03b2, and D1 dopamine receptors: a possible pathogenetic link? Neurobiol Aging. 2016;48:161\u201371.","journal-title":"Neurobiol Aging"},{"key":"293_CR167","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fncel.2020.00019","volume":"14","author":"D Toral-Rios","year":"2020","unstructured":"Toral-Rios D, Pichardo-Rojas PS, Alonso-Vanegas M, Campos-Pe\u00f1a V. GSK3\u03b2 and tau protein in Alzheimer\u2019s disease and epilepsy. Front Cell Neurosci. 2020;14:19.","journal-title":"Front Cell Neurosci"},{"issue":"4","key":"293_CR168","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1515\/revneuro-2017-0064","volume":"29","author":"N Garg","year":"2018","unstructured":"Garg N, Joshi R, Medhi B. Cracking novel shared targets between epilepsy and Alzheimer\u2019s disease: need of the hour. Rev Neurosci. 2018;29(4):425\u201342.","journal-title":"Rev Neurosci"},{"issue":"11","key":"293_CR169","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1080\/14656566.2018.1496237","volume":"19","author":"B Cretin","year":"2018","unstructured":"Cretin B. Pharmacotherapeutic strategies for treating epilepsy in patients with Alzheimer\u2019s disease. Expert Opin Pharmacother. 2018;19(11):1201\u20139.","journal-title":"Expert Opin Pharmacother"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-021-00293-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-021-00293-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-021-00293-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T21:14:49Z","timestamp":1699132489000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-021-00293-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,13]]},"references-count":169,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["293"],"URL":"https:\/\/doi.org\/10.1007\/s43440-021-00293-5","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,13]]},"assertion":[{"value":"16 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This manuscript is a review article and does not involve a research protocol requiring approval by the relevant institutional review board or ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}